Aminoglycoside resistance in Gram-negative blood isolates from various hospitals in Belgium and the Grand Duchy of Luxembourg
Open Access
- 1 October 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 44 (4) , 483-488
- https://doi.org/10.1093/jac/44.4.483
Abstract
A total of 1102 consecutive clinical blood isolates, including 897 Enterobacteriaceae and 205 non-fermenting bacilli, were obtained from 13 university and university-affiliated hospitals, which were divided into a Northern and a Southern group. Resistance to gentamicin, tobramycin, netilmicin, amikacin and isepamicin was determined using a microdilution technique according to NCCLS procedures. The overall mean resistance level was 5.9% for gentamicin, 7.7% for tobramycin, 7.5% for netilmicin, 2.8% for amikacin and 1.2% for isepamicin. Resistance to amikacin and isepamicin was significantly higher in the Northern hospitals than in the Southern hospitals. In total, 157 isolates were found not to be susceptible to aminoglycosides. By PCR, 179 aminoglycoside resistance mechanisms, i.e. 150 genes encoding modifying enzymes and 29 permeability mechanisms, were detected in 148 isolates. A resistance mechanism could not be detected in nine isolates. Moreover, in a further 14 isolates the resistance profile was not fully explained by the detected genes. The aac(6′)-I genes were found to be the most predominant resistance mechanism in both the Northern and Southern isolates, followed by aac(3)genes and permeability resistance. A total of 29 non-susceptible isolates harboured a combination of genes, 72.4% of which were a combination with the aac(6′)-Ib gene. The majority of these combinations were broad-spectrum combinations which represented 9.0% of the resistance mechanisms in non-susceptible Enterobacteriaceae and 19.3% in the non-fermenting bacilli.Keywords
This publication has 15 references indexed in Scilit:
- The Most Frequent Aminoglycoside Resistance Mechanisms--Changes with Time and Geographic Area: A Reflection of Aminoglycoside Usage Patterns?Clinical Infectious Diseases, 1997
- The emergence of resistance to amikacin in Serratia marcescens isolates from patients with nosocomial infectionInternational Journal of Antimicrobial Agents, 1996
- Serotypes and extended spectrum beta-lactam resistance in aminoglycoside resistant Pseudomonas aeruginosa isolates from two Belgian general hospitals: a seven year studyJournal of Hospital Infection, 1993
- Increased resistance to amikacin in a neonatal unit following intensive amikacin usageAntimicrobial Agents and Chemotherapy, 1992
- Alterations in the Microbial Flora and in the Incidence of Bacteremia at a University Hospital after Adoption of Amikacin as the Sole Formulary AminoglycosideClinical Infectious Diseases, 1992
- Correlation between aminoglycoside resistance profiles and DNA hybridization of clinical isolatesAntimicrobial Agents and Chemotherapy, 1991
- Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospitalAntimicrobial Agents and Chemotherapy, 1991
- Resistance to aminoglycoside antibiotics in Gram-negative bacilli and staphylococci isolated from blood. Report from a European collaborative studyJournal of Antimicrobial Chemotherapy, 1990
- Three-year survey of amikacin use and aminoglycoside resistance in a general hospital in BelgiumEuropean Journal of Clinical Microbiology & Infectious Diseases, 1988
- Comparison of aminoglycoside resistance patterns in Japan, Formosa, and Korea, Chile, and the United StatesAntimicrobial Agents and Chemotherapy, 1985